Roche's VENTANA FOLR1 (FOLR1-2.1) RxDx Assay Gets CE Mark …
11 hours ago · Roche's VENTANA RxDx Assay is a qualitative immunohistochemical assay using mouse monoclonal anti-FOLR1 clone FOLR1-2.1 intended for use in the assessment of folate receptor alpha (FR?) in ...
Roche receives CE Mark for VENTANA FOLR1 (FOLR1-2.1) RxDx Assay …
12 hours ago · The VENTANA FOLR1 (FOLR1-2.1) RxDx Assay detects the folate receptor 1 protein (FOLR1 or FRɑ), which is over-expressed in most ovarian cancers. The test identifies ovarian cancer patients ...
Roche receives CE Mark for VENTANA FOLR1 (FOLR1-2.1) RxDx Assay …
12 hours ago · Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has received CE Mark for its VENTANA® FOLR1 (FOLR1-2.1) RxDx Assay. This is the first immunohistochemistry (IHC) companion diagnostic ...
Roche receives CE Mark for VENTANA FOLR1 (FOLR1-2.1) RxDx Assay …
18 hours ago · VENTANA FOLR1 (FOLR1-2.1) RxDx Assay is a qualitative immunohistochemical assay using mouse monoclonal anti-FOLR1 clone FOLR1-2.1 intended for use in the assessment of folate receptor alpha (FR?) in formalin-fixed, paraffin-embedded epithelial ovarian cancer (EOC), including primary peritoneal cancer and primary fallopian tube cancer, tissue ...
Roche receives CE Mark for VENTANA FOLR1 (FOLR1-2.1) RxDx Assay …
12 hours ago · The VENTANA FOLR1 (FOLR1-2.1) RxDx Assay detects the folate receptor 1 protein (FOLR1 or FRɑ), which is over-expressed in most ovarian cancers. ... This certification follows the news earlier this year that the VENTANA FOLR1 (FOLR1-2.1) test had received pre-authorisation in Germany and Austria. This exceptional decision allowed clinicians and ...
Roche granted FDA Breakthrough Device Designation for blood …
May 22, 2024 · Roche announced today that the Tina-quant ® lipoprotein Lp(a) RxDx assay has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) to identify patients who may benefit from innovative Lp(a)-lowering therapy currently in development.
Roche receives FDA approval for the first companion diagnostic to ...
The new VENTANA CLDN18 (43-14A) RxDx Assay helps fulfill an unmet medical need by enabling clinicians to identify patients with gastric or gastroesophageal junction (GEJ) cancer who may benefit from a targeted treatment option.
Roche receives FDA approval for the first companion diagnostic to ...
Oct 18, 2024 · The new VENTANA CLDN18 (43-14A) RxDx Assay helps fulfil an unmet medical need by enabling clinicians to identify patients with gastric or gastroesophageal junction (GEJ) cancer who may...
Roche receives FDA approval for VENTANA FOLR1 (FOLR1-2.1) RxDx Assay …
Developed as a predictive biomarker, the VENTANA FOLR1 (FOLR1-2.1) RxDx Assay detects the folate receptor 1 protein (FOLR1 or FRɑ), which is over-expressed in most ovarian cancers. The new test identifies ovarian cancer patients eligible for targeted treatment with ELAHERE.
Roche's VENTANA FOLR1 (FOLR1-2.1) RxDx Assay Gets CE Mark …
11 hours ago · Swiss drug major Roche Group announced Monday that it has received CE Mark for its VENTANA FOLR1 (FOLR1-2.1) RxDx Assay, which identifies ovarian cancer patients eligible for targeted treatment with ELAHERE (mirvetuximab soravtansine).This is the first immunohistochemistry or IHC companion diagnostic test to be made widely available in Europe to help identify epithelial ovarian cancer or EOC ...
- Some results have been removed